Atrial fibrillation (AFib) is the most common form of irregular heartbeat (arrhythmia). People with AFib have many treatment options, including medications and medical procedures. However ...

Background Iron deficiency (ID) is common in patients with atrial fibrillation/flutter (AF), but its prognostic implications and optimal diagnostic criteria, particularly in those with and without ...

ESCAMBIA COUNTY, Fla. -- More than 12 million Americans are estimated to suffer from atrial fibrillation by 2030, according to doctors. Now, there's a new provider hoping to make treatment more ...

When an older adult with atrial fibrillation, or Afib, stops taking an anticoagulant, it raises their risk of stroke or heart attack more than risks of bleeding, according to a new report ...

Atrial fibrillation (AFib ... While the results for persistent AFib are still in early stages, early studies suggest that modifications to the RF ablation technique could improve outcomes for ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway Abelacimab is currently in ...

Basel: Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, ...